Media Library

Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.

ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).

Erenumab has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficancy in migraine prevention.

Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.

The menace of noncommunicable diseases (NCDs) like cardiovascular disease, diabetes and cancer in the developing world is increasing. New solutions like Novartis Access are needed to ensure more people are trained to prevent, diagnose and treat these diseases, and patients have access to affordable quality medicines.

Welcome to the first-ever Museum of MS, a place that celebrates how people living with multiple sclerosis (MS) overcome the challenges or adapt to the symptoms of MS in their daily lives.

Novartis Access is partnering with the International Committee of the Red Cross to provide access to medicines for Syrian refugees and their host communities in Lebanon.

Novartis brought together European stakeholder including NGOs, academia, governments as well as Novartis associates to present and debate Novartis Access, a new program intended to increase access to medicine for patience at ever level of income. Novartis associates share their reactions.

On November 29, global health experts from the Novartis Foundation, Novartis Access, NGOs and academia gathered at our Basel headquarters to discuss the chronic disease challenge in developing countries.

Miriam, a patient with Anaplastic Lymphoma Kinase (ALK+) non-small cell lung cancer (NSCLC), and her husband Joel describe their experience with the disease.

Anne Marie, a patient with Anaplastic Lymphoma Kinase (ALK+) non-small cell lung cancer (NSCLC), describes her experience with the disease.